Allogene Therapeutics, Inc. ALLO
Allogene Therapeutics, Inc. (Nasdaq: ALLO) is an oncology drug developer. Its lead program, cema-cel (cemacabtagene ansegedleucel, previously ALLO-501A), is in Phase 3 for first-line consolidation treatment for patients newly diagnosed with large B-cell lymphoma (LBCL) with minimal residual disease (MRD) following 1L chemoimmunotherapy. Its next catalyst on record is ALLO-329 (RESOLUTION): clinical and translational data presentation at ACR Convergence (November 9, 2026).
Upcoming catalysts
- November 9, 2026ALLO-329 (RESOLUTION) — clinical and translational data presentation at ACR Convergence
We will present updated clinical and translational data from RESOLUTION at the 2026 American College of Rheumatology (ACR) Convergence on November 9, 2026.
Next further out: cema-cel (ALPHA3) — next clinical update (H1 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| cema-cel (ALPHA3 trial) | first-line consolidation LBCL with MRD | cell therapy | Phase 3 |
| ALLO-316 | advanced or metastatic clear cell renal cell carcinoma (RCC) | cell therapy | Phase 1 |
| ALLO-329 (RESOLUTION trial) | autoimmune diseases (SLE, IIM, SSc) | cell therapy | Phase 1 |
| BCMA CAR (with or without CD70 Dagger) | oncology (BCMA+ cancers, likely multiple myeloma) | cell therapy | Pre-clinical |
| DLL3 CAR (with or without CD70 Dagger) | small cell lung cancer and other neuroendocrine tumors | cell therapy | Pre-clinical |
Recent results and decisions
- Apr 13, 2026positive Interim futility analysis (24 pts): MRD negativity 58.3% (7/12) with cema-cel vs 16.7% (2/12) observation; no CRS, ICANS or GvHD; primary EFS endpoint remains blinded.
At the protocol-defined data cutoff date, 58.3% (7/12) of patients in the cema-cel arm achieved MRD negativity compared to 16.7% (2/12) in the observation arm.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.